ArticleBMC public health2025
Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors associated with eating behaviors of young and middle-aged adults with overweight and obesity: a systematic review.Frontiers in public health · 2026Pooled it
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.Diabetes, obesity & metabolism · 2026Trial
- Serum zinc, copper status and Cu/Zn ratio in overweight and obesity: associations with oxidative stress, adipokines, and cardiometabolic traits in adult women.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
- Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee-For-Service Beneficiaries.Diabetes, obesity & metabolism · 2026Article
- Understanding the socio-economic and health burden of obesity: a 10-year retrospective analysis of population-wide administrative healthcare data.Reviews in endocrine & metabolic disorders · 2026Review
- Article
- Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.Obesity pillars · 2026Article
- Trends in Diagnosing Obesity: The CALOR Study.Obesity (Silver Spring, Md.) · 2026Article
- Long-Term Cost and Health Impact of a Digital Obesity Intervention in Germany: Economic Modeling Study.JMIR formative research · 2026Article
- Clinical and Economic Burden Among People with Knee Osteoarthritis and Obesity in the United States: A Retrospective Analysis.Rheumatology and therapy · 2026Article
- Palmitoylethanolamide in Human and Animal Obesity.Molecules (Basel, Switzerland) · 2026Review
- Clinical characteristics, treatment patterns, and healthcare utilization among children, adolescents, and young adults with obesity in the United States.Obesity pillars · 2026Article
- Genome-wide DNA methylation signatures in blood associated with pediatric obesity.Clinical epigenetics · 2026Article
- Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023.Obesity (Silver Spring, Md.) · 2026Article
- Optimizing Obesity Management With GLP-1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review.Obesity science & practice · 2026Article
- Bariatric Surgery and Renal Function: A Mid-Term Prospective Analysis of Estimated Glomerular Filtration Rate Dynamics in Adults with and without Diabetes Mellitus.Obesity surgery · 2026Article
- Is there an association between distal femoral morphology and periprosthetic femoral fracture risk after Posterior-Stabilized Total Knee Arthroplasty?International orthopaedics · 2026Article
- Prevalence of Overweight and Obesity in the Era of CFTR Modulators in Patients with Cystic Fibrosis.Nutrients · 2026Article
- One-year Weight Loss and Metabolic Outcomes of Single Anastomosis Sleeve Jejunal Bypass: A Retrospective Report with Reference to Roux-en-Y Gastric Bypass.Obesity surgery · 2026Article
- Impact of Menopausal Status and Female Reproductive Aging on the Outcomes of Bariatric Surgery: A Narrative Review.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the substantial burden of obesity in the United States (US), data on the comprehensive range of comorbidities in different age groups is limited. This study assessed the prevalence of various comorbidities among people diagnosed with obesity (as per ICD-10 diagnosis code) across age cohorts and compared how they differ from people without obesity.
methodsThis cross-sectional study analyzed individuals from all four regions (Midwest, Northeast, South, and West) of the US who had continuous insurance coverage from 2018 to 2020, using a large health insurance claims database (Merative™ MarketScan
resultsOf 6,935,911 individuals, people with a diagnosis of obesity accounted for 22.0%, 33.6%, and 34.4% in the 18-39 years, 40-64 years, and ≥ 65 years age groups, respectively. Within age strata, the mean age of people with obesity was comparable with those without obesity. Comorbidity burden was significantly higher among people with obesity, but increased with age in both obesity and non-obesity groups. Comorbidities with highest prevalence in people with obesity included: (i) hypertension (18-39 years: 29.0%, 40-64 years: 66.2%, ≥ 65 years: 89.4%), (ii) dyslipidemia (18-39 years: 28.1%, 40-64 years: 65.4%, ≥ 65 years: 88.0%), (iii) depression or anxiety (18-39 years: 44.1%, 40-64 years: 39.0%, ≥ 65 years: 38.9%), and (iv) prediabetes (18-39 years: 17.1%, 40-64 years: 32.2%, ≥ 65 years: 35.3%). Notably, increased prevalence of cardiometabolic risk factors such as hypertension and dyslipidemia began at an earlier age in people with obesity as compared with those without obesity. Ratio of prevalence between obesity and non-obesity groups was highest for the 18-39 years age group, as compared to older groups. Disorders such as obstructive sleep apnea, osteoarthritis, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, coronary heart diseases (CHD), and chronic kidney diseases also exhibited substantial burden among those with obesity.
conclusionsIn this claims study, hypertension and dyslipidemia were the leading comorbidities in people with obesity, with an increasing prevalence with age. The burden of cardiometabolic comorbidities among the younger age group suggested potential risk for early onset of CHD in later life. Understanding the range of obesity-related comorbidities seen in this claims data may encourage healthcare professionals and healthcare systems to systematically diagnose and better manage these disorders. Further research using additional data sources can offer a more accurate view of the prevalence of obesity and its impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.